NY Times:FDA says Pirfenidone benefits NOT Meaningful
"The agency also questioned whether the benefit provided by the drug even in the successful trial was meaningful. The drug cannot repair damage already done to the lungs and make patients better.
But it did seem, at least in one trial, to modestly slow the decline of lung function compared to a placebo. It did not prolong patients’ lives by a statistically significant amount, though the trial was too small to have detected such an effect unless it were huge..."